Shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.91 and traded as low as $4.62. Ampliphi Biosciences shares last traded at $4.71, with a volume of 37,501 shares.
Ampliphi Biosciences Price Performance
The stock has a 50-day simple moving average of $5.85 and a 200-day simple moving average of $8.11.
About Ampliphi Biosciences
Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company’s core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.
The company’s lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.
See Also
- Five stocks we like better than Ampliphi Biosciences
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
